Introduction: The role of mass spectrometry in biomolecule analysis has become paramount over the last several decades ranging in the analysis across model systems and human specimens. Accordingly, the presence of mass spectrometers in clinical laboratories has also expanded alongside the number of researchers investigating the protein, lipid, and metabolite composition of an array of biospecimens. With this increase in the number of omic investigations, it is important to consider the entire experimental strategy from sample collection and storage, data collection and analysis.Areas covered: In this short review, we outline considerations for working with clinical (e.g. human) specimens including blood, urine, and cerebrospinal fluid, with emphasis on sample handling, profiling composition, targeted measurements and relevance to disease. Discussions of integrated genomic or transcriptomic datasets are not included. A brief commentary is also provided regarding new technologies with clinical relevance.Expert opinion: The role of mass spectrometry to investigate clinically related specimens is on the rise and the ability to integrate multiple omics datasets from mass spectrometry measurements will be crucial to further understanding human health and disease.

中文翻译：

---

基于质谱的临床样品多组学分析的注意事项。

简介：在过去的几十年中，质谱在生物分子分析中的作用已变得至为重要，涉及模型系统和人体标本的分析。因此，随着研究一系列生物标本的蛋白质，脂质和代谢产物组成的研究人员数量的增加，临床实验室中质谱仪的存在也有所扩大。随着眼科研究数量的增加，重要的是要考虑从样品收集，存储，数据收集和分析的整个实验策略。涵盖的领域：在这篇简短的综述中，我们概述了处理临床（例如人体）标本的注意事项包括血液，尿液和脑脊液，重点是样品处理，轮廓分析，针对性的测量以及与疾病的相关性。不包括对综合基因组或转录组数据集的讨论。还提供了有关与临床相关的新技术的简短评论。专家意见：质谱在研究临床相关标本方面的作用正在上升，整合质谱测量中的多个组学数据集的能力对于进一步了解人类健康至关重要和疾病。